Lonza Group AG

Swiss CDMO giant, biopharmaceutical and sterile injection (drug product) capacity covers Switzerland Stein, Visp, Basel. Its filling line supports liquid and lyophilized vials, pre-filled syringes (PFS) and cartridges, using isolator technology and innovative lyophilization; the Stein base is expanding the large-scale biopharmaceutical DP facility (about 20,000 m ², CHF 500 million investment, put into production in 2027), adding cassette/pre-filled syringe filling and vial lyophilization capabilities. Basel is a centre of excellence for process development and characterization. Through Annex 1 compliance, more than 150 biopharmaceutical DP technology transfers, serving monoclonal antibodies, bioconjugates, viral vectors, etc.